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Abstract
Background: Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive
pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia. LTOT is usually provided
by a stationary oxygen concentrator and is recommended to be used for at least 15–18 h a day. Several studies have
demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD,
even in those not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end
stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the
severity of desaturation occurring during sleep. The primary objective of the International Nocturnal Oxygen (INOX)
trial is to determine, in patients with COPD not qualifying for LTOT but who present significant nocturnal arterial
oxygen desaturation, whether nocturnal oxygen provided for a period of 3 years decreases mortality or delay the
prescription of LTOT.
Methods: The INOX trial is a 3-year, multi-center, placebo-controlled, randomized trial of nocturnal oxygen therapy
added to usual care. Eligible patients are those with a diagnosis of COPD supported by a history of past smoking and
obstructive disease who fulfill our definition of significant nocturnal oxygen desaturation (i.e., ≥ 30% of the recording
time with transcutaneous arterial oxygen saturation < 90% on either of two consecutive recordings). Patients allocated
in the control group receive room air delivered by a concentrator modified to deliver 21% oxygen. The comparison is
double blind. The primary outcome is a composite of mortality from all cause or requirement for LTOT. Secondary
outcomes include quality of life and utility measures, costs from a societal perspective and compliance with oxygen
therapy. The follow-up period is intended to last at least 3 years.
Discussion: The benefits of LTOT have been demonstrated whereas those of nocturnal oxygen therapy alone have
not. The INOX trial will likely determine whether supplemental oxygen during sleep is effective in reducing mortality,
delaying the need for LTOT and improving health-related quality of life in patients with COPD who desaturate overnight.
Trial registration: Current Controlled Trials ISRCTN50085100; ClinicalTrials.gov NCT01044628 (date of registration:
January 6, 2010).
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Background
Chronic obstructive pulmonary disease (COPD) repre-
sents a major health issue worldwide. For instance, while
4% of Canadians aged 35 to 79 self-reported being diag-
nosed with COPD, direct measurements of lung function
from the Canadian Health Measures Survey indicate that
13% of Canadians had a lung function score indicative of
COPD. Among individuals aged > 40 with a smoking
history of at least 20 pack-years visiting a primary care
physician for any reason, one in five met spirometric cri-
teria for COPD [1]. COPD represents the fourth leading
cause of mortality in Canada [2]. Continuous (i.e., long-
term) oxygen therapy (LTOT) is one of the few compo-
nents of the management of COPD that improves survival
and it is only indicated in patients with severe daytime
hypoxemia [3, 4]. LTOT is usually provided by a stationary
oxygen concentrator and should be used for at least 15 h a
day [5].
Sleep-related non-apneic oxygen desaturation often
occurs in patients not qualifying for LTOT [6–10] and is
considered by many physicians as an indication for pro-
viding nocturnal oxygen therapy (NOT). This perceived
indication stems from the suggestion that the natural
progression of COPD to its end stages of severe hypox-
emia, right heart failure, and death may be dependent
upon the severity of desaturation occurring during sleep
[11–13]. This attractive hypothesis is supported by the fact
that hypoxemic episodes during sleep are accompanied by
increases in pulmonary arterial pressure [14–16] and often
by important cardiac arrhythmias[17, 18], both alleviated
by nocturnal oxygen supplementation. Over the long run,
NOT may halt the progression of long-standing cor pul-
monale [4, 14] and may prolong survival [3].
Practice guidelines regarding the indications for NOT
in COPD not qualifying for conventional LTOT are pres-
ently imprecise. Because of this, a number of these pa-
tients are currently treated with NOT [19] despite the fact
that the clinical benefits of NOT have yet to be confirmed.
Three randomized trials directly addressed the issue of the
effectiveness of NOT in patients not qualifying for LTOT
who desaturate overnight [20–22]. Two looked at the ef-
fect of NOT on survival at 2- to 3-year follow-up [21, 22].
Both trials were negative but were underpowered. Even
their meta-analysis could not determine whether NOT
improves survival, with a pooled mortality odds ratio of
0.97 and a wide 95% confidence interval (CI: 0.41–2.31)
from which both detrimental and positive effects of NOT
on survival could not be excluded [23]. We complemented
this mortality meta-analyses by conducting a systematic
review and meta-analysis of the composite outcome of
mortality or requirement for LTOT (a surrogate marker of
disease progression) and found no significant difference
between the treated and the control groups (pooled odds
ratio: 1.57 [95% CI: 0.75–3.26]; unpublished data).
Accordingly, the primary objective of the International
Nocturnal Oxygen (INOX) trial is to determine, in patients
with COPD not qualifying for LTOT who exhibit signifi-
cant nocturnal arterial oxygen desaturation, whether NOT
provided for a period of 3 years decreases mortality or the
requirement for LTOT. Its secondary objectives are to
examine whether NOT improves disease-specific quality of




The INOX trial is a 3-year, multi-center, randomized,
double-blind, placebo-controlled trial of NOT, with
intention-to-treat analysis.
Participants
The trial is currently conducted in 27 university-
affiliated clinical sites in Canada, Portugal, Spain and
France (Appendix).
Inclusion criteria
To be included in the trial, patients must fulfill all the
following criteria:
 a diagnosis of COPD supported by a history of past
smoking and obstructive disease: forced expiratory
volume in 1 s (FEV1) < 70% predicted, FEV1/forced
vital capacity (FVC) < 70% and a total lung capacity
by body plethysmography > 80% predicted;
 stable COPD at study entry, as demonstrated by no
acute exacerbation and no change in medications for
at least 6 weeks before enrollment in the trial;
 non-smoker for at least 6 months before enrollment
in the trial;
 fulfilling our definition of nocturnal oxygen
desaturation (see below);
 ability to give informed consent.
Exclusion criteria
The exclusion criteria are the following:
 patients with severe hypoxemia fulfilling the usual
criteria for LTOT at study entry [3]: PaO2 ≤ 55
mmHg; OR PaO2 ≤ 59 mmHg with clinical evidence
of at least one of the following: (1) peripheral edema
(cor pulmonale); (2) hematocrit ≥ 55%; (3) right
ventricular hypertrophy (P pulmonale on ECG: 3
mm in leads II, III, aVf;
 patients with proven sleep apnea (defined by an
apnea/hypopnea index of ≥ 15 events/hour [24]) or
suspected sleep apnea on oximetry tracings;
 patients currently using NOT;
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 patients with known left heart or congenital heart
diseases, interstitial lung diseases, bronchiectasis as
the main cause of obstructive disease, lung carcinoma,
severe obesity (body mass index ≥ 40 kg/m2), or any
other disease that could influence survival.
Operational definition of nocturnal desaturation
Significant “nocturnal desaturation” is defined on the home
oximetry as ≥ 30% of the recording time (time in bed)
with a transcutaneous arterial oxygen saturation < 90%
[21, 25, 26]. Continuous nocturnal saturation (SaO2)
monitoring is obtained with the PalmSAT 2500™ oximeter
only (Nonin Medical Inc., Plymouth, MN, USA). Only re-
cordings of at least 4-h duration are accepted. All patients
undergo two oximetric studies [27] separated from each
other by ≤ 2 weeks. Each oximetry recording is classified
in one of three categories:
 significant nocturnal desaturation (i.e., ≥ 30% of the
recording time with a transcutaneous arterial oxygen
saturation < 90%) without suspicion of associated
sleep apnea (i.e., steady tracing with non-periodic
variation in saturation throughout sleep – Fig. 1a);
 nocturnal desaturation with suspicion of associated
sleep apnea (i.e., cyclical changes in saturation in
addition to the desaturations – Fig. 1b);
 no significant nocturnal desaturation (i.e., < 30%
of the recording time with a saturation < 90%).
 patients with at least one abnormal recording
demonstrating significant nocturnal desaturation
with no suspicion of associated sleep apnea on both
oximetries are directly eligible, without further testing.
Patients with an oximetry tracing suggestive of sleep
apnea are excluded, unless sleep apnea can be ruled out
on the basis of a formal sleep study performed off-
protocol. In such cases, the investigator must submit to
the coordinating center the results of either a complete
laboratory or full ambulatory polysomnography confirming
the absence of sleep apnea before the patient is randomized
[28]. Sleep apnea is defined as an apnea/hypopnea index
≥ 15 [24]. A flow diagram detailing the diagnostic proce-
dures following the screening home oximetries is provided
in Fig. 2.
Intervention
Patients are randomly assigned to 3 years of treatment
with either home NOT therapy or sham therapy with
ambient air. Before randomization, patients are assessed
and optimal pharmacological and non-pharmacological
therapy is provided according to the clinician’s judgment.
Because of the extended follow-up period, new therapies
may emerge or ongoing trials may demonstrate positive
effects of currently available treatment modalities on mor-
tality. We therefore monitor and record co-interventions
that arise throughout the trial period. Because clinical
practice often varies across centers and new therapies are
often introduced in different ways throughout centers, the
randomization is stratified by centers.
Fig. 1 Nocturnal oximetry tracings in patients with COPD not qualifying for LTOT. a Significant nocturnal oxygen desaturation (>30% of the
recording time with a saturation < 90%) without periodic variations in saturation, a tracing not suggestive of sleep apnea. b Significant nocturnal
oxygen desaturation with cyclical changes in saturation suggesting sleep apnea, a tracing suggestive of sleep apnea
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Intervention arm
NOT is delivered overnight from an electrically-powered
oxygen concentrator (NewLife Intensity Oxygen Con-
centrator, AirSep Corporation, Buffalo, NY, USA). The
concentrator provides a constant source of oxygen from
ambient air using a molecular sieve that removes nitro-
gen and water from air to deliver 95% oxygen at flow
rates of up to 4 l/min. Patients are instructed to receive
NOT throughout the night. The flow of oxygen is that
allowing the nocturnal saturation to be > 90% for ≥ 90%
of the recording time. This is assessed by the mean of
pulse oximetry during a full-night recording (test night).
Two liters of oxygen per minute are given during a first
test night. If this flow of oxygen is not enough to keep
the saturation > 90% for ≥ 90% of the recording time,
then an additional test night is needed, with the oxygen
flow rate increased by 1 l/min per night, up to 4 l/min.
Control arm
The patients allocated to the control group receive ambi-
ent air delivered overnight through the same concentrator
rendered ineffective by bypassing the sieve beds. The sham
concentrators have the same external appearance as the
effective ones, allowing the trial to be double-blinded. We
have received approval by Health Canada in order to
proceed with the modifications on the oxygen concen-
trators; such approval by a regulatory agency was not
mandatory in the European Community. The patients
in the control group are also submitted to air flow ad-
justment (Fig. 3). To preserve blinding, patients in the
control group are randomly submitted to additional test
oximetries, with the airflow rate increased by 1 l/min, up
to 4 l/min. The results of the oximetry performed during
those nights are sent to the coordinating center but are
disregarded.
Compliance issues
Objective daily duration of oxygen therapy (or placebo)
is measured using the concentrators’ counter clock re-
cording the number of hours of utilization. This infor-
mation is recorded during regular home visits scheduled
every 4 months. Patient receiving oxygen or sham ther-
apy during at least 70% of the total time in bed over the
3-year trial are considered as compliant. Total time in
bed is estimated from the typical daily time in bed that
is self-reported at baseline.
Outcomes
Primary outcome
The primary outcome of the INOX trial is a composite
of “all-cause mortality” or “requirement for LTOT”. All-
cause mortality is preferred over disease-specific mortality
because of difficulties in classifying causes of death [29]
and the lack of validity of death certificates in patients
with COPD [30]. The widely accepted criteria for LTOT
derived from the Nocturnal Oxygen Therapy Trial [3] are
used to define “requirement of LTOT”. These criteria are
met in either of the two following clinical circumstances:
 In stable patients:
Patients may become severely hypoxemic over time
due to progressive deterioration of the disease that
characterizes its natural course. In such circumstances,
the requirement for LTOT is captured through
periodic surveillance. At each protocol-based follow-up
visit, patients are submitted to pulse oximetry at rest. If
pulse oximetry at rest gives a saturation ≥ 92%, then
direct arterial blood gas measurement is not required.
Otherwise, arterial blood gas must be sampled for
direct PaO2 measurement. Patients whose PaO2 falls
below 56 mmHg during the follow-up period are
offered conventional LTOT [3]. The trial end-point is
then reached.
 In unstable patients:
Patients may become severely but temporarily
hypoxemic during an acute exacerbation of COPD
necessitating hospitalization. In such circumstances,
Fig. 2 Diagnostic procedures. In case of oximetry tracing suggestive of
sleep apnea, patients are excluded, unless sleep apnea is ruled out on
the basis of a formal sleep study (either of Type-1 or Type-2 – shaded
area) performed off-protocol
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short-term oxygen therapy may be prescribed for a
short period of time, especially if oxygen therapy
allows the patient to be safely discharged from the
hospital [31]. Any decision regarding the maintenance
of oxygen therapy (i.e., the requirement of LTOT
following short-term oxygen therapy) must be made
after a period of clinical stability of at least 30 days
[31]. Reevaluation must occur within 12 weeks after
the end of the treatment of the exacerbation. The
study primary endpoint is reached only when LTOT
criteria are met.
Secondary outcomes
Disease-specific quality of life (St. George’s Respiratory
Questionnaire [32–34]), generic quality of life (SF-36
[35, 36]) and associated utility scores (SF-6D [37]), costs
and health care utilization are secondary outcomes. The
estimates of the cost of COPD treatment for the two
intervention groups will be based on the utilization of
the intervention resources during the study period. The
social and health care perspectives will be adopted. Pro-
fessional time, intervention materials and health care
utilization will be considered.
Sample size
In their randomized trial, the French group reported a
3-year mortality of 20% [21] and a rate of LTOT prescrip-
tion of 29%, with 40% of the study population reaching
one or the other of the endpoints. These figures are con-
sistent with the survival rate of patients with COPD re-
ported in the literature [38], including a large North
American study (n = 985) [39]. Therefore, we anticipate
the 3-year event rate (i.e., mortality or requirement for
LTOT) among patients not receiving NOT to be around
40%. We targeted a 30% relative reduction in this compos-
ite outcome in the experimental group (i.e., an event rate
in the control group of 40% and an event rate of 28% in
the NOT group, or an absolute difference in event rates of
12%). This absolute difference is consistent with the min-
imal clinically important difference elicited by Canadian
pulmonologists in a national survey that we conducted
prior to the INOX trial [26]. The level of statistical signifi-
cance is set at p = 0.05 (two-sided). Translating this in
terms of our proposed log rank test, we calculated that
300 patients per group (total sample size: 600) will provide
us with a power of 90% [40].
Recruitment
In a feasibility study, we demonstrated that 40% of the
patients with moderate-to-severe COPD not qualifying
for continuous oxygen are nocturnal desaturators [10].
In our survey of Canadian pulmonologists, we found that,
on average, 30% of the respondents’ practice (including
that of our co-investigators) is dedicated to the care of pa-
tients with COPD [26]. This information clearly demon-
strates that nocturnal oxygen desaturation in patients with
Fig. 3 Nocturnal oxygen flow titration procedure
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COPD is not a rare occurrence and that the investiga-
tors have access to a large pool of potentially eligible
patients.
Participant timeline
Time schedule of assessments and follow-up visits for
participants is reported in the Table 1.
Allocation
The randomization process consists of a computer-gen-
erated random listing of the two treatment allocations
blocked by variable blocks of four and six in alternance and
stratified by site. Randomization is through central alloca-
tion and coordinated by the Laboratoire de télématique
biomédicale (LTB) of the Respiratory Health Network of
the Fonds de recherche du Québec – Santé (FRQS). Physi-
cians and research staff are unaware of the treatment allo-
cation prior to or following randomization. At the time of
randomization, each patient is provided with a site-specific
study number according to the randomization schedule.
The results of the randomization is only communicated by
the LTB to the individual responsible for the preparation,
delivery and installation of the home concentrators and
oxygen flow titration.
Data collection and management
Standardized case report forms have been developed
specifically for the trial. Completed forms are periodic-
ally sent by the participating centers to the Coordinating
centre for verification and data entry though a secured
website using range checks for data values. The stored
data is secured at the LTB. Clinical centres are reim-
bursed only after complete data is transmitted to the
Coordinating center.
Data monitoring
An independent Data and Safety Monitoring Board
(DSMB) assists and advises the Steering Committee to
protect the validity and credibility of the trial. The DSMB
operates according to the terms of a charter that was de-
veloped according to the DAMOCLES Study Group’s rec-
ommendations [41]. The DSMB receives and reviews
annually the progress and accruing data of the trial and
provides advice on the conduct of the trial to the Steering




The primary analysis will follow an intent-to-treat ap-
proach. The distribution of time to achievement of the
primary composite outcome (all-cause mortality or re-
quirement for LTOT) will be estimated by the Kaplan-
Meier method, and the difference between the two
study groups will be evaluated with a log-rank test. The
estimated relative risk of mortality or requirement for
LTOT with its 95% confidence interval will be computed.
Multivariable analyses with the Cox proportional-hazards
model will be used to estimate the simultaneous effects of
prognostic factors (including gender, age, FEV1, and co-
morbidities) and on the composite outcome. Differences
will be considered to be statistically significant at the 0.05
level (two-sided).
Subgroup analyses
The effect of nocturnal oxygen may depend on the se-
verity of nocturnal desaturation which may be defined in
terms of % of time in bed with a saturation < 90% or in
terms of mean saturation throughout the recording time.
Accordingly, in addition to the traditional threshold of
30% of the time with a saturation < 90%, the effect of
Table 1 Schedule of follow-up procedures, including a fourth year of follow-up according to the Steering Committee’s 2012
recommendation
Time line (months)
0 4 8 12 16 20 24 28 32 36 40 44 48
Consent form √
Baseline/follow-up general health information √ √ √ √ √
Nocturnal oxymetry √
Pulse oxymetry √ √ √ √ √ √ √ √ √ √
Arterial blood gas √ √a √a √a √a √a √a √a √a √a √a √a √
Pulmonary function tests (spirometry, lung volumes and DLCO) √ √ √ √ √
Quality-of-life questionnaires √ √ √ √ √
Health Care questionnaire (follow-up call or visit)b √ √ √ √ √ √ √ √ √ √ √ √
Home visits for compliancec √ √ √ √ √ √ √ √ √ √ √ √
aDepending on the result of the arterial saturation in oxygen measured by pulse oximetry
bHealth care utilization is measured through telephone contacts with patients every 2 months
cHome visits are performed by home care service provider staff
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nocturnal oxygen will be analyzed according to various
thresholds of desaturation.
Cost effectiveness analysis
An incremental cost effectiveness analysis will be under-
taken to assess the efficiency of NOT. The overall costs
and effects of the two groups will be used to calculate in-
cremental cost effectiveness ratios according to the follow-
ing equation: R = (CT −CC)/(ET − EC) =ΔC/ΔE, where R is
the incremental cost effectiveness ratio, CC and EC are the
means of the control group costs and effect, respectively,
CT and ET are the means of the treatment group costs and
effect, respectively, and ΔC and ΔE are the incremental cost
and incremental effect, respectively [42]. Protocol-specific
costs will be disregarded in the control group. The effect of
therapy will be defined in terms of mortality, life-years
and utility.
Discussion
The INOX protocol development, funding and imple-
mentation result from a series of international consulta-
tions with trialists and expert clinicians in the area of
COPD. Although its methodology is straightforward,
debates took place in the early stages of the study re-
garding important aspects of the trial including (1) the
need for blinding, (2) its composite outcome, and (3)
the exclusion of sleep apnea.
Need for blinding
Sham concentrators are more expensive than effective
ones. Obtaining permission from the Canadian regula-
tory agency to produce such equipment added to the
complexity of the trial implementation. Therefore, the
first area of discussion was about the need of placebo in
a trial whose primary outcome includes mortality. How-
ever, mortality is not the only endpoint. The primary
outcome is also composed of the requirement for LTOT
which is determined at least in part by the actions of cli-
nicians. Although it follows strict criteria and guidelines
defined in this protocol, there is conceivably potential
for more aggressive surveillance (monitoring) of arterial
blood gases in those in the control group, leading to an
increased likelihood of prescription of LTOT in this
group. In this regard, INOX could not be conducted
other than as a double-blind, placebo-controlled trial.
Composite outcome
Although we realize the difficulties related to composite
outcomes in clinical trials [43, 44], the requirement of
LTOT must represent an endpoint of this trial for clin-
ical and methodological reasons. The primary reason is
that the condition of participants may deteriorate to the
point that LTOT is required. This situation is particu-
larly problematic because LTOT compulsorily includes
sleep time (and therefore NOT). If mortality was the
only outcome, and if LTOT was prescribed because of
disease progression to a patient allocated to NOT, NOT
would then become LTOT (which is of proven effective-
ness in improving survival in COPD). Similarly, if LTOT
was prescribed in a patient allocated to the control
group, it would then represent an important contamin-
ation. Both situations would represent important threats
to the validity of our trial.
We understand that the choice of a composite outcome
requires that its components (1) are of similar importance,
(2) occur with similar frequency [43]. In order to support
our view that our composite outcome is appropriate, we
first derived utility scores (SF-6D scores) [37] in 102 pa-
tients with oxygen-dependent COPD. The mean utility
score was 0.60 (SD: 0.11) [45]. For comparison, this utility
score is worse than that attached to a large myocardial
infarction, stroke leaving permanent moderate deficit, or
dissecting or ruptured aortic aneurysm [46], three condi-
tions considered in the cardiovascular literature as appro-
priate in composite outcomes that include mortality [44].
Regarding the relative frequency of the two components
of the composite outcome, we have already made the
point that mortality and requirement for LTOT should
occur with similar incidence during the trial (see Sample
size, above).
Exclusion of sleep apnea
COPD and obstructive sleep apnea (OSA) are common
conditions. The combination of COPD and sleep apnea is
referred to as the “overlap syndrome” [47]. A population-
based study indicated that both conditions are not linked
by common pathophysiological mechanisms, and that
their association is only by chance [48]. The routine
utilization of sleep studies in patients with COPD to
distinguish between sleep apnea and nocturnal oxygen de-
saturation alone (i.e. without sleep apnea) is controversial.
On one hand, the access to diagnostic facilities for patients
with suspected sleep apnea in Canada and many other
jurisdictions is unfortunately very limited [49, 50], and the
requirement of a polysomnography for all patients in the
frame of this study would be unrealistic. On the other
hand, 42% of the Canadian pulmonologists think that all
COPD patients with significant nocturnal desaturation
should have a polysomnography to rule out sleep apnea
[26]. In a blind comparison of home nocturnal oximetry
and laboratory polysomnography in consecutive patients
with COPD and nocturnal oxygen desaturation, we found
that, in patients with significant nocturnal oxygen desatur-
ation, home nocturnal oximetry has high negative predict-
ive value for the diagnosis of OSA (unpublished data).
However, home nocturnal oximetry has a poor positive
predictive value for the diagnosis of OSA [51]. It is on the
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basis of this study that we constructed the algorithm for
the patients’ screening and selection (Fig. 2).
Important protocol modification
Despite our continuing efforts to increase the patients’
accrual rate across participating centers, recruitment
has been a challenge since the beginning of the trial in
November 2009. It has become obvious that the target
sample size of 600 patients would not be reached within a
reasonable period of time. In order to increase the number
of events, the Steering Committee strongly recommended
in 2012 that the follow-up period be extended from 3 to 4
years. The rationale to initially propose a 3-year trial was
from the results of the British trial [4], in which 500 days
elapsed before any effect of continuous oxygen therapy ap-
peared, when compared to no oxygen therapy at all. By ex-
tending the follow-up period to 4 years, we anticipate that
50% of those allocated in the control group will reach the
primary outcome. Accordingly, aiming at a 30% relative
reduction in event rate in the experimental group (i.e., an
event rate in the control group of 50% and an event rate
of 35% in the NOT group, or an absolute difference in
event rates of 15%), we calculated that 160 patients per
group would provide us with a power of 80% (type-1 error:
0.05, two-sided). During this fourth year of follow-up, the
same procedures as in Year 3 apply.
Implication for practice
Why should clinicians be interested in nocturnal oxygen
desaturation? COPD clearly represents a significant bur-
den of health care systems wherever it has been assessed
[52]. Home oxygen therapy comes in second place (only
after hospitalizations) among the most expensive health
care resources for COPD. In the Canadian cohort of the
Confronting COPD Survey (3265 individuals; mean age:
63 years; 44% female), outpatient treatment for COPD
accounted for over 30% of total direct costs, the majority
of which was for home oxygen therapy. Overall, home
oxygen therapy accounted for almost 20% of the entire
annual direct costs for COPD [53]. Informal surveys
among respiratory home care programs in the province
of Quebec (Canada) indicate that 15–20% of those who
receive home oxygen therapy through these programs
have been prescribed oxygen for nocturnal utilization
only. A more formal survey of Canadian pulmonologists
revealed that 87% of them had already prescribed noctur-
nal oxygen in COPD [26]. Given the resources allocated to
nocturnal oxygen therapy, its prescription should there-
fore be justifiable by demonstrating an improvement in
clinical outcomes other than the mere correction of noc-
turnal oxygen desaturation.
In the most recent COPD international guidelines
[54, 55], the issue of nocturnal oxygen therapy is not
addressed. Two workshops of the National Heart, Lung,
and Blood Institute identified nocturnal oxygen therapy
as a research priority in COPD [56, 57]. This situation
stimulated our planning and implementation of the INOX
trial.
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